師資
張路，南方科技大學(xué)生物醫(yī)學(xué)工程系副教授，博士生導(dǎo)師。博士師從中山大學(xué)帥心濤教授（國(guó)家杰青），畢業(yè)后赴美加入加州大學(xué)戴維斯分校開展博士后研究，師從組合化學(xué)及分子醫(yī)學(xué)領(lǐng)域權(quán)威專家Kit S. Lam教授。張博士針對(duì)臨床癌癥精準(zhǔn)成像診斷和高效治療面臨的難題開展研究工作，以臨床癌癥實(shí)際需求為導(dǎo)向，基于“活體自組裝”研究理念，提出了活體調(diào)控細(xì)胞膜蛋白功能新策略，拓展單組分納米材料抗腫瘤領(lǐng)域的發(fā)展方向，構(gòu)建了多種納米材料精準(zhǔn)遞送體系，探索納米顆粒在體內(nèi)的多種作用機(jī)制，突破傳統(tǒng)癌癥診療瓶頸，取得了有國(guó)際影響力的創(chuàng)新性成果，實(shí)現(xiàn)了前沿基礎(chǔ)研究的臨床轉(zhuǎn)化應(yīng)用。張博士以第一及通訊作者在Nat. Nanotechnol., Nano Lett., ACS Nano, Adv. Funct. Mater., Hepatology, Theranostics等高水平期刊上發(fā)表多篇SCI論文；研發(fā)技術(shù)及納米藥劑已獲授權(quán)多項(xiàng)國(guó)際專利，并正在開展3項(xiàng)納米藥劑臨床轉(zhuǎn)化研究，其中1項(xiàng)被美國(guó)FDA批準(zhǔn)進(jìn)入臨床一期研究，2項(xiàng)進(jìn)入臨床前開發(fā)研究。目前研究?jī)?nèi)容主要集中于1）活體原位纖維化自組裝體系，2）樹枝狀大分子納米精準(zhǔn)遞送診療體系。所開發(fā)的新型活體細(xì)胞表面重塑生物技術(shù) (In Vivo Cell Surface Remodeling, IVCSRM) 是當(dāng)前科學(xué)研究的熱點(diǎn)之一，該技術(shù)具有很高臨床轉(zhuǎn)化前景。與傳統(tǒng)策略相比，該技術(shù)創(chuàng)新性不僅體現(xiàn)在可以在活體環(huán)境下原位直接特異性調(diào)控，而且既能夠調(diào)控內(nèi)源性膜蛋白的功能又能夠在細(xì)胞膜表面重塑新的外源性多功能基團(tuán)。課題組與哈佛醫(yī)學(xué)院、斯坦福大學(xué)、加州大學(xué)伯克利分校及加州大學(xué)戴維斯分校的研究團(tuán)隊(duì)建立了有長(zhǎng)期深度合作關(guān)系。
工作 & 教育背景
2022.12-至今 副教授（PI） 南方科技大學(xué) 生物醫(yī)學(xué)工程系
2021.08-2022.12 助理教授（PI） 南方科技大學(xué) 生物醫(yī)學(xué)工程系
2016.09-2021.07 博士后, 美國(guó)加州大學(xué)戴維斯分校，醫(yī)學(xué)中心，生物化學(xué)與分子醫(yī)學(xué)系
導(dǎo)師：Kit S Lam教授 (組合化學(xué)和分子醫(yī)學(xué)領(lǐng)域權(quán)威專家)
2011.09-2016.06 博士 (碩博連讀)，中山大學(xué)，化學(xué)與化學(xué)工程學(xué)院
導(dǎo)師：帥心濤教授 (國(guó)家杰出青年科學(xué)基金獲得者)
研究方向
多功能生物醫(yī)用體系的開發(fā)及應(yīng)用
針對(duì)臨床癌癥精準(zhǔn)成像診斷和高效治療面臨的難題開展研究工作，以臨床癌癥實(shí)際需求為導(dǎo)向，基于“活體自組裝”研究理念，提出了活體調(diào)控細(xì)胞膜蛋白功能新策略，拓展單組分納米材料抗腫瘤領(lǐng)域的發(fā)展方向，構(gòu)建了多種納米材料精準(zhǔn)遞送體系，探索納米顆粒在體內(nèi)的多種作用機(jī)制，突破傳統(tǒng)癌癥診療瓶頸，取得了有國(guó)際影響力的創(chuàng)新性成果，實(shí)現(xiàn)了前沿基礎(chǔ)研究的臨床轉(zhuǎn)化應(yīng)用。以第一及通訊作者在Nat. Nanotechnol., Nano Lett., ACS Nano, Adv. Funct. Mater., Hepatology, Theranostics等高水平期刊上發(fā)表多篇SCI論文，并一直致力于研究成果的臨床醫(yī)學(xué)應(yīng)用和產(chǎn)業(yè)轉(zhuǎn)化，其研發(fā)技術(shù)及藥劑已獲授權(quán)2項(xiàng)國(guó)際專利，并正在開展3項(xiàng)納米藥劑臨床轉(zhuǎn)化研究，其中1項(xiàng)被美國(guó)FDA批準(zhǔn)進(jìn)入臨床一期研究，2項(xiàng)進(jìn)入臨床前開發(fā)研究。
研究?jī)?nèi)容主要集中于（1）活體原位纖維化自組裝體系和（2）樹枝狀大分子納米精準(zhǔn)遞送診療體系，已有十年的研發(fā)經(jīng)驗(yàn)，牢牢扎根在化學(xué)、材料、生物、醫(yī)學(xué)和工程交叉學(xué)科研究的前沿，目前所開發(fā)的新型活體細(xì)胞表面重塑生物技術(shù) (In Vivo Cell Surface Remodeling, IVCSRM) 是當(dāng)前科學(xué)研究的熱點(diǎn)之一，該技術(shù)具有極高臨床轉(zhuǎn)化前景，具有開創(chuàng)性研究的標(biāo)志特征，通過對(duì)新型納米醫(yī)藥、生物技術(shù)的研究，滿足當(dāng)今臨床醫(yī)學(xué)上對(duì)特異性、智能性、精準(zhǔn)性、高效性、安全性的疾病診療需求。與傳統(tǒng)策略相比，該技術(shù)創(chuàng)新性不僅體現(xiàn)在可以在活體環(huán)境下原位直接特異性調(diào)控，而且既能夠調(diào)控內(nèi)源性膜蛋白的功能又能夠在細(xì)胞膜表面重塑新的外源性多功能基團(tuán)。
代表性成果
文章
1) Lu Zhang#, Di Jing#, Nian Jiang, Tatu Rojalin, Christopher M. Baehr, Dalin Zhang, Wenwu Xiao, Yi Wu, Zhaoqing Cong, Jian Jian Li, Yuanpei Li, Lei Wang*, Kit S. Lam*. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nature Nanotechnology 2020, 15 (2), 145-153. (IF: 39.213)
2) Lu Zhang, Yi Wu, Xingbin Yin, Zheng Zhu, Tatu Rojalin, Wenwu Xiao, Dalin Zhang, Yanyu Huang, Longmeng Li, Christopher M. Baehr, Xingjian Yu, Yousif Ajena, Yuanpei Li, Lei Wang* and Kit S. Lam*. Tumor Receptor-Mediated In Vivo Modulation of the Morphology, Phototherapeutic Properties, and Pharmacokinetics of Smart Nanomaterials. ACS Nano 2021, 15 (1), 468-479 (IF: 15.881)
3) Lu Zhang#, Di Jing#, Lei Wang, Yuan Sun, Jian Jian Li, Brianna Hill, Fan Yang, Yuanpei Li*, Kit S. Lam*. Unique Photochemo-Immuno-Nanoplatform against Orthotopic Xenograft Oral Cancer and Metastatic Syngeneic Breast Cancer. Nano Letters 2018, 18 (11), 7092-7103. (IF: 11.189)
4) Lu Zhang#, Tinghui Yin#, Bo Li, Rongqin Zheng*, Chen Qiu, Kit S. Lam*, Qi Zhang, Xintao Shuai*. Size-Modulable Nanoprobe for High-Performance Ultrasound Imaging and Drug Delivery against Cancer. ACS Nano 2018, 12 (4), 3449-3460. (IF: 15.881)
5) Lu Zhang, Yanyu Huang, Aaron Raymond Lindstrom, Tzu-Yin Lin, Kit S Lam, Yuanpei Li*. Peptide-based materials for cancer immunotherapy. Theranostics 2019, 9 (25), 7807-7825. (IF: 11.556)
6) Hao Wu#, Lu Zhang#(co-first), Jinfan Yang, Ruonan Bo, Hongxu Du, Kai Lin, Dalin Zhang, Mythili Ramachandran, Yingbin Shen, Yangxi Xu, Xiangdong Xue, Zhao Ma, Aaron Raymond Lindstrom, Randy Carney, Tzu-Yin Lin, Yuanpei Li. Rotatable Aggregation-Induced-Emission/Aggregation Caused-Quenching Ratio Strategy for Real-Time Tracking Nanoparticle Dynamics. Advanced Functional Materials 2020, 30 (15), 1910348. (IF: 18.808)
7) Yu Guo#, Jing Wang#, Lu Zhang#(co-first), Shunli Shen#, Ruomi Guo, Yang Yang*, Wenjie Chen, Yiru Wang, Guihua Chen*, Xintao Shuai*. Theranostical Nanosystem-Mediated Identification of An Oncogene and Highly Effective Therapy in Hepatocellular Carcinoma. Hepatology 2016, 63 (4), 1240-1255. (IF: 17.425)
8) Lu Zhang#, Hong Xiao#, Jingguo Li, Du Cheng*, Xintao Shuai*. Co-delivery of doxorubicin and arsenite with reduction and pH dual-sensitive vesicle for synergistic cancer therapy. Nanoscale 2016, 8 (25), 12608-12617. (IF: 7.79)
9) Mengru Cai, Liuying Qin, Longtai You, Yu Yao, Huimin Wu, Zhiqin Zhang, Lu Zhang* (co-corresponding), Xingbin Yin*, Jian Ni*. Functionalization of MOF-5 with Mono-Substituents: Effects on Drug Delivery Behavior. RSC Advances 2020, 10(60), 36862-36872. (IF: 3.361)
10) Lu Zhang#, Hao Wu#, Yuanpei Li*, Kit S. Lam*. Reversible Cross-Linked Polymeric Micelles for Drug Delivery. Elsevier, 2020. (Academic Treatise)
11) Zhaoqing Cong, Lu Zhang, Si-Qi Ma, Kit S.Lam, Fei-Fei Yang*, YongHong Liao*. Size-Transformable Hyaluronan Stacked Self-Assembling Peptide Nanoparticles for Improved Transcellular Tumor Penetration and Photo-Chemo Combination Therapy. ACS Nano 2020, 14(2), 1958-1970. (IF: 15.881)
12) Hong Xiao, Jin He, Xiaoxia Li, Bo Li, Lu Zhang, Yong Wang*, Du Cheng, Xintao Shuai*. Polymeric Nanovesicles as Simultaneous Delivery Platforms with Doxorubicin Conjugation and Elacridar Encapsulation for Enhanced Treatment of Multidrug-Resistant Breast Cancer. Journal of Materials Chemistry B 2018, 6(45), 7521-7529. (IF: 6.331)
13) Hao Wu#, Lu Zhang#(co-first), Yuanpei Li*; Kit S. Lam*; Stimuli-Responsive Materials in Theranostics. Royal Society of Chemistry, 2018. (Academic Treatise)
14) Jingguo Li, Lu Zhang, Yujie Lin, Hong Xiao, Mingxiang Zuo, Du Cheng, Xintao Shuai*. A pH-Sensitive Prodrug Micelle Self-Assembled from MultiDoxorubicin-Tailed Polyethylene Glycol for Cancer Therapy. RSC Advances. 2016, 6(11), 9160-9163. (IF: 3.361)
專利
1) Kit S. Lam; Lu Zhang; Cyanine-based telodendrimers and uses for treating cancer, 2020-5-3, WIPO, PCT/US2019/049080.
2) Kit S. Lam; Lu Zhang; Smart peptides and transformable nanoparticles for cancer immunotherapy, 2021-2-18, WIPO, PCT/US2020/046495
臨床轉(zhuǎn)化應(yīng)用
1) 樹枝狀大分子包載紫杉醇 (Paclitaxel，PTX) 的納米藥劑用于膀胱癌治療，已經(jīng)被美國(guó)FDA批準(zhǔn)進(jìn)入一期臨床研究 (PEG5K-CA4-Porphyrin4, PLZ4-PEG5K-CA8, PTX)。臨床轉(zhuǎn)化項(xiàng)目編號(hào)(117888)。
2) 開發(fā)了多種GMP及GLP級(jí)別的樹枝狀大分子聚合物包載化療藥和免疫藥物的納米藥劑, 化療藥(Doxorubicin, Paclitaxel等)，免疫藥物(Resiquimod, Imiquimod等)；并已獲準(zhǔn)應(yīng)用于鼠、兔、貓和狗等動(dòng)物的膀胱癌、口腔癌、卵巢癌和乳腺癌等模型的臨床前研究。臨床前轉(zhuǎn)化項(xiàng)目編號(hào)(132838、135780)。
主持或參加科研項(xiàng)目
1) National Cancer Institute (NCI), 1R01CA247685-01, HER2 targeting transformable nanotherapeutic platform against HER2+ cancers, 2020.02 - 2025.01, $572,096 (Each year).
2) Department of Defense (DOD), W81XWH-19-1-0204, Delivery of targeting nano-photo-imiquimod to greatly enhance check point blockade immunotherapy of patients with advanced bladder cancer, 2019.07 - 2023.06, $1,037,215 (Each year).
3) Department of Defense (DOD), W81XWH-19-1-0159, Novel nano-photo-immunotherapy against ovarian cancer, 2019.06 - 2022.06, $234,000 (Each year).
4) National Cancer Institute (NCI), 5R01CA115483-13, Therapeutic targeting agents for ovarian cancer, 2015.01 - 2021.04, $334,535 (Each year).
5) National Institute of Biomedical Imaging and Bioengineering (NIBIB), 2R01EB012569-09, Targeting nanotherapeutics against murine and feline oral cancer, 2010.12 - 2021.05, $518,074 (Each year).